Commercial Expansion And Project Turing Will Transform Operations

Published
03 Apr 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$7.75
2.2% undervalued intrinsic discount
15 Aug
US$7.58
Loading
1Y
109.4%
7D
-0.4%

Author's Valuation

US$7.8

2.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on04 Aug 25
Fair value Increased 6.90%

Analysts raised their price target for Performant Healthcare to $7.75, citing its leading role in healthcare payment integrity, favorable momentum from its new New York Medicaid contract, and confidence in its scalable, diversified business model. Analyst Commentary Recognition of Performant as a leading technology-enabled healthcare payment integrity vendor.

Shared on01 May 25
Fair value Decreased 0.55%

Shared on24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 0.55%

AnalystConsensusTarget has increased revenue growth from 7.9% to 9.7%, decreased profit margin from 4.6% to 3.5%, increased future PE multiple from 91.5x to 120.6x and increased shares outstanding growth rate from 0.0% to 0.0%.